NICE waves through breast cancer drugs following price deals
The National Institute for Health and Care Excellence is backing routine NHS funding for Pfizer’s Ibrance and Novartis’ Kisqali to treat certain forms of breast cancer, after the firms agreed to provide them at a reduced price under the new process for appraising medicines.
Read More
